Teladoc Health and Amwell: Assessing the AI-Driven Growth in Virtual Care

The virtual care market is no longer just about replacing office visits. A new wave of AI applications is dramatically expanding its Total Addressable Market, moving the sector from a simple consultation platform into a core operational layer for healthcare systems. This shift is creating a much larger growth runway for leaders like Teladoc Health and Amwell.

AI is enabling entirely new use cases that go far beyond patient visits. Teladoc Health, for instance, has launched an AI-powered workforce safety monitoring solution designed to detect escalating incidents in real time, using video and audio analysis to identify aggressive language and gestures. This directly addresses a critical pain point-healthcare workers are five times more likely to experience violence than those in other industries-and expands the virtual care platform into a vital safety and risk management tool. Similarly, Amwell has partnered with Suki, an AI voice assistant, to integrate clinical workflow automation directly into its Converge platform. This tool helps clinicians complete notes 72% faster, tackling administrative burnout and freeing up time for patient care. These are not incremental features; they are new revenue streams that deepen customer relationships and lock in platform usage.

This technological expansion is happening at a pivotal moment for the broader healthcare sector. After a period of muted investor interest, the sector saw a significant rally late in 2025, driven largely by the emergence of tangible AI applications and a reduction in policy overhang. As noted, the sector's renewed momentum is expected to post year-over-year earnings growth for the fourth quarter, with almost three-fourths of companies trading above their 50-day average. This renewed investor appetite provides a favorable backdrop for virtual care companies demonstrating AI-led innovation and scalability.

Amwell's strategic pivot to a subscription-based model is a key part of this growth narrative. By shifting its revenue mix toward recurring contracts, the company is moving away from transactional fees and toward a more predictable, scalable income stream. This model aligns with the expansion of its platform into high-value, operational services like AI-driven clinical support and workforce safety. It signals a maturation from a pure-play telehealth provider to a comprehensive care delivery enablement platform, which is critical for capturing a larger share of healthcare systems' budgets as AI becomes embedded in daily operations.

The bottom line is that AI is the catalyst transforming virtual care from a niche channel into a central nervous system for modern healthcare. The market's growth is being fueled by these new, high-margin applications, and companies that successfully integrate AI into core workflows are positioned to capture the largest share of this expanding TAM.

Financial Scalability and the Profitability Imperative

The path to sustainable profitability is the central financial challenge for virtual care leaders, and the evidence shows a stark divergence in their trajectories. While both Teladoc Health and Amwell are investing heavily in AI, their current cost structures and revenue models create very different scalability profiles.

Teladoc's growth narrative is currently under pressure from a key unit. The company's BetterHelp mental health unit is experiencing member losses and weakness, which is dragging down its path to profitability. This is a material overhang, as investors must now weigh Teladoc's AI investments and new partnerships against this persistent drag. The company's financial health hinges on stabilizing this segment and demonstrating that its broader platform can generate sufficient margin improvement to offset the losses. Its projected path to profitability, which includes a forecast for $2.7 billion in revenue and $235.6 million in earnings by 2028, assumes a successful turnaround that remains unproven in the near term.

Amwell, by contrast, is showing tangible progress toward financial sustainability. The company is making headway on its goal of achieving positive operational cash flow by 2026. This is supported by a more favorable revenue mix, with its software revenue growing 47% year-over-year and representing nearly 60% of total revenue. This shift away from transactional visits toward a subscription-based model is a classic scalability play, providing more predictable income. Furthermore, Amwell is actively improving its cost structure, having cut research and development expenses by 12.2% and sales and marketing spend by 32.4% in its most recent quarter. This disciplined approach to cost control, combined with a move away from expensive, one-time customizations toward a standardized platform, is directly targeting higher and more stable margins.

The industry-wide trend is clear: the era of costly, bespoke implementations is giving way to standardized, scalable platforms. This shift is critical for improving unit economics. As Amwell's executives noted, moving toward a more centralized and standard platform experience reduces complexity and cost, making the business model more resilient and easier to scale. For growth investors, this means the financial scalability of a virtual care company is increasingly tied to its ability to lock in recurring revenue and control operating expenses, not just to grow visit volumes. Amwell's current financial trajectory suggests it is executing this playbook more effectively than Teladoc, which remains in a defensive position trying to stabilize a key revenue stream.

Competitive Positioning and Catalysts

The institutional confidence signaled by a major healthcare-focused fund is a clear vote of confidence in Teladoc's long-term growth story. In the third quarter of 2025, investment firm Oracle Investment Management increased its holdings in Teladoc Health by 324,416 shares, adding an estimated $2.13 million in value. This move propelled Teladoc to become the fund's 4th-largest holding, accounting for 3.4% of its assets under management. For a growth investor, this kind of concentrated bet from a specialized healthcare investor suggests a belief that Teladoc's AI investments and platform expansion can ultimately overcome its current challenges.

Amwell, meanwhile, is building its competitive moat through strategic partnerships that embed AI directly into its high-traffic platform. Its collaboration with Suki AI integrates an AI-powered assistant into the Converge platform, which serves over 90 million covered lives. This isn't a standalone tool; it's designed to streamline clinical workflows for providers, helping them complete notes 72% faster. This deep integration into a platform used by thousands of hospitals creates a powerful lock-in effect, making it harder for competitors to displace Amwell as a core care delivery layer.

The catalysts for each company are now starkly different. For Teladoc, the primary near-term test is stabilizing its BetterHelp mental health unit. The company's entire investment narrative hinges on demonstrating that AI-driven innovations and cost discipline can offset this persistent drag. The upcoming J.P. Morgan Healthcare Conference will be a key stage to assess management's plan. For Amwell, the catalyst is execution on its financial turnaround. The company is making tangible progress toward its goal of positive operational cash flow by 2026, but it must achieve this while simultaneously scaling its AI offerings. Its recent cost cuts, including a 32.4% reduction in sales and marketing spend, show a disciplined focus on the path to profitability.

The key watchpoints are clear. Teladoc must show that its AI initiatives can reverse the member losses in BetterHelp and accelerate its path to sustainable earnings. Amwell must hit its 2026 cash flow target while continuing to grow its high-margin software revenue, which is already up 47% year-over-year. The winner in this AI-driven wave will be the company that not only innovates but also converts that innovation into scalable, profitable growth.